Tenaya Therapeutics, Inc. Share Price & Technical Analysis
TNYA · $0.80 (+3.90%)
Healthcare / Biotechnology
$0.80
+3.90%
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricula…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
14% return in May, 8% avg return in past 3 year May month.
20% return in 2026, 42% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 14% | -25% | 17% | 0% | 14% | – | – | – | – | – | – | – | 20% |
| 25 | -27% | 0% | -40% | -17% | 0% | 50% | 17% | 57% | 45% | -12% | -7% | -50% | 17% |
| 24 | 31% | 37% | -13% | -13% | -9% | -28% | 13% | -23% | -30% | 0% | 89% | -61% | -6% |
| 23 | 55% | -9% | -10% | 89% | 33% | -18% | -17% | -19% | -36% | -28% | 6% | 68% | 115% |
| 22 | -37% | -6% | 3% | -23% | -26% | -16% | -16% | -6% | -34% | -7% | -4% | -26% | -198% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$215.94M
P/E ratio
—
52W high
$2.35
52W low
$0.42
Volume
15,73,664
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Tenaya Therapeutics, Inc. share price today?
- Tenaya Therapeutics, Inc. (TNYA) last traded around $0.80 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TNYA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TNYA. Download the app for real-time alerts.
- How can I analyze Tenaya Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.